The AI That Eliminated Cold Chain from mRNA Vaccines Just Changed How You Design a Phase I

A new AI framework, AGENT, uses Bayesian optimization to design mRNA vaccine formulations that remain stable at 37°C for over two months, eliminating the need for ultra-cold storage in Phase I trials. This breakthrough challenges the cold-chain assumptions embedded in trial protocols and opens opportunities for decentralized, more diverse vaccine trial designs.

This Wire brief sits within Fusion42's coverage of Health.